LONDON (Reuters) - Britain’s medicines regulator did not cut any corners in the rolling review process that led it to approve the Pfizer vaccine against COVID-19, the regulator’s chief executive said on Wednesday, describing the review as thorough and rigorous.
“It’s very clear that separate teams have been working in parallel to deliver the most rigorous review of this vaccine. No corners have been cut,” June Raine said.
“Our expert scientists and clinicians have worked round the clock, carefully, methodically, poring over tables and analyses and graphs on every single piece of data, hundreds, over a thousand pages of data and, absolutely critically, analysing the pre-clinical evidence, the clinical trials, the manufacturing and quality controls, and then down to the final sampling.”
Reporting by Guy Faulconbridge and Estelle Shirbon; editing by William James
Our Standards: The Thomson Reuters Trust Principles.